Founded in 1929 by Henri Beaufour, Ipsen is a global French pharmaceutical company headquartered in Boulogne-Billancourt, France. The company's core mission is to improve patients' lives through innovative medicines in oncology, rare diseases, and neuroscience. Ipsen develops and markets a range of specialized medicines and serves customers worldwide, focusing on providing advanced therapeutic solutions.
Notable figures associated with Ipsen include Marc de Garidel, the Non-executive Chairman, and David Loew, the Chief Executive Officer. Ipsen is publicly traded on Euronext Paris under the ticker IPN and is a component of the CAC Mid 60. In 2021, the company reported a revenue of €2.87 billion and an operating income of €1.01 billion. Ipsen's impactful contributions to the pharmaceutical industry are reflected in its robust financial performance and its commitment to addressing complex medical needs globally.
